Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

Active Systemic Lupus Erythematosus Clinical Trial

Official title:

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04931563
• Other study ID #: D3468C00003
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 13, 2021
• Est. completion date: June 5, 2025

Study information

• Verified date: March 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).

Description:

This is a Phase III, multicenter, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg anifrolumab versus placebo in participants with moderate to severe, autoantibody positive SLE while receiving SOC treatment. The study will be performed in participants aged 18 to 70 years of age. Participants with a confirmed diagnosis of moderate to severe active SLE and are currently receiving SOC comprising of oral corticosteroids (OCSs) and/or antimalarial, and/or immunosuppressants, either alone or any combination of them, for a required duration of treatment at a stable dose, as described in the inclusion criteria shall be included. Participants must have eligible scores for SLEDAI-2K, BILAG-2004, and PGA as confirmed by the DACRT. Eligible participants will be randomised in a 1:1 ratio to receive either a fixed intravenous dose of 300 mg anifrolumab plus SOC or placebo plus SOC every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 264
• Est. completion date: June 5, 2025
• Est. primary completion date: April 3, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Key inclusion criteria:

1. Aged 18 to 70 years.

2. Body weight = 40 kg.

3. Confirmed diagnosis of SLE(1997 ACR revised criteria) for = 24 weeks.

4. Must be receiving at least one of the following SOC regimens at screening:

1. oral prednisone monotherapy: = 7.5 mg/day and = 40 mg/day, stable for > 2 weeks;

2. Immunosuppressant(s) with or without OCS and must be stable for = 8 weeks;

3. Oral prednisone plus immunosuppressant: start date, stability and maximum dose required.

5. At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith.

6. SLEDAI-2K score = 6 points at screening and "Clinical" SLEDAI-2K score =4 points at both screening and Day1(randomisation), and BILAG with at least 1 level A organ system or 2 level B organ system, and PGA score = 1.0 at screening.

7. Chest imaging shows no clinically significant abnormalities (unless due to SLE).

8. No evidence or medical history of active TB, indeterminate TB should be referred to a TB specialist.

9. All participants should use effective contraception methods as protocol requests.

10. Any negative SARS-CoV-2 RT-PCR test result at screening and no known or suspected COVID-19 infection or exposure within 2 weeks prior to screening and between screening and randomisation visits.

Key exclusion criteria:

1. History or current diagnose of clinically significant non-SLE related vasculitis, severe or unstable neuropsychiatric SLE, active severe SLE-driven renal disease, catastrophic anti-phospholipid syndrome, inflammatory joint or skin disease other than SLE, non-SLE disease that has required treatment of certain dosage of corticosteroid.

2. History or evidence of suicidal ideation or suicidal behavior.

3. History or current diagnose of MTCD or overlap syndrome, unless overlap with RA or MTCD which has developed into SLE.

4. History of recurrent infection requiring hospitalization and IV antibiotics, or opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization, or clinically significant chronic infection within 3 months, or recent infection still under treatment.

5. History of immunodeficient condition, HIV positive included.

6. Confirmed HBsAg positive, or HBcAb positive and HBV DNA detectable, or hepatitis C antibody positive.

7. History of severe case of herpes zoster.

8. Herpes zoster, CMV or EB infection which has not completely resolved within 12 weeks before screening.

9. Acute COVID-19 infection or history of severe COVID-19.

10. History of cancer, apart from cured squamous or basal cell carcinoma and cervical cancer in situ.

11. Female participants with abnormal pap smear results.

12. Prior receipt of anifrolumab ,or any commercially available Janus kinase (JAK) inhibitor = 12 weeks or Bruton's tyrosine kinase (BTK) inhibitor = 24weeks prior to signing the ICF; any investigational medicinal product(small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater.

13. Known history of allergy to any component of the IP formulation or protein related products.

14. Receipt of any of the following:

1. Intramuscular or IV glucocorticosteroids within 6 weeks;

2. Any live or attenuated vaccine within 8 weeks;

3. Any restricted medication listed in protocol;

4. Blood transfusion within 4 weeks. 15 Regular use of > 1 NSAID within 2 weeks or receipt of fluctuating doses of a NSAID within 2 weeks.

16. Certain laboratory test results requirements. 17. Concurrent enrolment in another clinical study. 18. History or current alcohol, drug or chemical abuse within 1 year. 19. Major surgery within 8 weeks or planned elective major surgery.

Related Conditions & MeSH terms

• Active Systemic Lupus Erythematosus
• Lupus Erythematosus, Systemic

Intervention

Biological:
• Anifrolumab
Intravenous infusion (IV)

Drug:
• placebo
Intravenous infusion (IV)

Locations

Country	Name	City	State
China	Research Site	Baoding
China	Research Site	Baotou
China	Research Site	Beijing
China	Research Site	Beijing
China	Research Site	Beijing
China	Research Site	Beijing
China	Research Site	Beijing
China	Research Site	Bengbu
China	Research Site	Binzhou
China	Research Site	Changchun
China	Research Site	Changsha
China	Research Site	Chuangchun
China	Research Site	Guangzhou
China	Research Site	Guangzhou
China	Research Site	Guilin
China	Research Site	Hangzhou
China	Research Site	Hengyang
China	Research Site	Jieyang
China	Research Site	Jinan
China	Research Site	Jining
China	Research Site	Kunming
China	Research Site	Lanzhou
China	Research Site	Linyi
China	Research Site	Luoyang
China	Research Site	Nan Chong
China	Research Site	Nanchang
China	Research Site	Nanjing
China	Research Site	Nanyang
China	Research Site	Shanghai
China	Research Site	Shengyang
China	Research Site	Shenyang
China	Research Site	Shenzhen
China	Research Site	Shijiazhuang
China	Research Site	Suzhou
China	Research Site	Tianjin
China	Research Site	Urumqi
China	Research Site	Wenzhou
China	Research Site	Wuhan
China	Research Site	Wuhan
China	Research Site	Wuxi
China	Research Site	Xiamen
China	Research Site	Xinxiang
China	Research Site	Yinchuan
China	Research Site	Zaozhuang City
China	Research Site	Zhengzhou
Hong Kong	Research Site	Hong Kong
Hong Kong	Research Site	Hong Kong
Korea, Republic of	Research Site	Gwangju
Korea, Republic of	Research Site	Jung-gu
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Suwon-si
Philippines	Research Site	Davao City
Philippines	Research Site	Iloilo
Philippines	Research Site	Iloilo City
Philippines	Research Site	Lipa City
Philippines	Research Site	Manila
Philippines	Research Site	Quezon City
Taiwan	Research Site	Kaohsiung
Taiwan	Research Site	New Taipei
Taiwan	Research Site	Taichung
Taiwan	Research Site	Taichung
Taiwan	Research Site	Taipei
Taiwan	Research Site	Taipei
Taiwan	Research Site	Taipei City
Taiwan	Research Site	Tao-Yuan
Thailand	Research Site	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

China,  Hong Kong,  Korea, Republic of,  Philippines,  Taiwan,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in proportion of participants who are responders between anifrolumab and placebo	Composite endpoint (BICLA),a composite binary endpoint defined by meeting all of the following criteria: Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as =1 new BILAG-2004 A or =2 new BILAG-2004 B; No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of >0 points in SLEDAI-2K; No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of =0.30 points on a 3-point PGA visual analogue scale (VAS)	Week 52
Secondary	The proportion of participants who achieve SRI(4) response at week 52	SRI(4) response defined by meeting all of the following criteria: Reduction from baseline of = 4 points in the SLEDAI-2K; No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline; No worsening from baseline in the participants' lupus disease activity defined by an increase =0.30 points on a 3-point PGA VAS;	Week 52
Secondary	The proportion of participants who achieve an oral corticosteroid (OCS) dose =7.5 mg/day at Week 40, which is maintained through Week 52 in the subgroup of those with baseline OCS =10 mg/day	Maintained OCS reduction defined by meeting all of the following criteria: Achieve an OCS dose of =7.5 mg/day prednisone or equivalent by Week 40; Maintain an OCS dose =7.5 mg/day prednisone or equivalent from Week 40 to Week 52	Week 52
Secondary	Annualized flare rate	Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit	Week 52